Murine Flt3 ligand expands distinct dendritic cells with both tolerogenic and immunogenic properties

Journal of Immunology

Volumn 170, Issue 7, 2003, Pages 3554-3564

  Miller, George ^a   Pillarisetty, Venu G ^a   Shah, Alaap B ^a   Lahrs, Svenja ^a   DeMatteo, Ronald P ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CD4 ANTIGEN; CD45 ANTIGEN; FLT3 LIGAND; GAMMA INTERFERON; GLYCOPROTEIN P 15095; INTERLEUKIN 10; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COLORECTAL CARCINOMA; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; GENE OVEREXPRESSION; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MALE; MELANOMA CELL; MOUSE; NATURAL KILLER CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SPLEEN CELL; TUMOR GROWTH;

EID: 0037377907     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.170.7.3554     Document Type: Article

References (51)

1. Banchereau, J. and R. M. Steinman. 1998. Dendritic cells and the control of immunity. Nature 392:245.
2. Anjuere, F., P. Martin, I. Ferrero, M. L. Fraga, G. M. del Hoyo, N. Wright, and C. Ardavin. 1999. Definition of dendritic cell subpopulations present in the spleen, Peyer's patches, lymph nodes, and skin of the mouse. Blood 93:590.
3. Suss, G., and K. Shortman. 1996. A subclass of dendritic cells kills CD4 T cells via Fas/Fas-ligand-induced apoptosis. J. Exp. Med. 183:1789.
4. Amakata, Y., Y. Fujiyama, A. Andoh, K. Hodohara, and T. Bamba. 2001. Mechanism of NK cell activation induced by coculture with dendritic cells derived from peripheral blood monocytes. Clin. Exp. Immunol. 124:214.
5. + dendritic cells from a common myeloid progenitor. Science 290:2152.
6. + dendritic cells expressing indoleamine 2,3-dioxygenase. J. Immunol. 167:708.
7. Grohmann, U., R. Bianchi, E. Ayroldi, M. L. Belladonna, D. Surace, M. C. Fioretti, and P. Puccetti. 1997. A tumor-associated and self antigen peptide presented by dendritic cells may induce T cell anergy in vivo, but IL-12 can prevent or revert the anergic state. J. Immunol. 158:3593.
8. Grohmann, U., M. L. Belladonna, R. Bianchi, C. Orabona, E. Ayroldi, M. C. Fioretti, and P. Puccetti. 1998. IL-12 acts directly on DC to promote nuclear localization of NF-κB and primes DC for IL-12 production. Immunity 9:315.
9. Corinti, S., C. Albanesi, A. la Sala, S. Pastore, and G. Girolomoni. 2001. Regulatory activity of autocrine IL-10 on dendritic cell functions. J. Immunol. 166:4312.
10. Grohmann, U., F. Fallarino, S. Silla, R. Bianchi, M. L. Belladonna, C. Vacca, A. Micheletti, M. C. Fioretti, and P. Puccetti. 2001. CD40 ligation ablates the tolerogenic potential of lymphoid dendritic cells. J. Immunol. 166:277.
11. Gabbianelli, M., E. Pelosi, E. Montesoro, M. Valtieri, L. Luchetti, P. Samoggia, L. Vitelli, T. Barberi, U. Testa, S. Lyman, et al. 1995. Multi-level effects of Flt3 ligand on human hematopoiesis: expansion of putative stem cells and proliferation of granulomonocytic progenitors/monocytic precursors. Blood 86:1661.
12. Jacobsen, S. E., O. P. Veiby, J. Myklebust, C. Okkenhaug, and S. D. Lyman. 1996. Ability of Flt3 ligand to stimulate the in vitro growth of primitive murine hematopoietic progenitors is potently and directly inhibited by transforming growth factor-β and tumor necrosis factor-α. Blood 87:5016.
13. Veiby, O. P., F. W. Jacobsen, L. Cui, S. D. Lyman, and S. E. Jacobsen. 1996. The Flt3 ligand promotes the survival of primitive hemopoietic progenitor cells with myeloid as well as B lymphoid potential: suppression of apoptosis and counteraction by TNF-α and TGF-β. J. Immunol. 157:2953.
14. McKenna, H. J., K. L. Stocking, R. E. Miller, K. Brasel, T. De Smedt, E. Maraskovsky, C. R. Maliszewski, D. H. Lynch, J. Smith, B. Pulendran, et al. 2000. Mice lacking Flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells. Blood 95:3489.
15. Rosnet, O., S. Marchetto, O. deLapeyriere, and D. Birnbaum. 1991. Murine Flt3, a gene encoding a novel tyrosine kinase receptor of the PDGFR/CSFIR family. Oncogene 6:1641.
16. Lyman, S. D., K. Stocking, B. Davison, F. Fletcher, L. Johnson, and S. Escobar. 1995. Structural analysis of human and murine Flt3 ligand genomic loci. Oncogene 11:1165.
17. McClanahan, T., J. Culpepper, D. Campbell, J. Wagner, K. Franz-Bacon, J. Mattson, S. Tsai, J. Luh, M. J. Guimaraes, M. G. Mattei, et al. 1996. Biochemical and genetic characterization of multiple splice variants of the Flt3 ligand. Blood 88:3371.
18. Lyman, S. D., L. James, T. Vanden Bos, P. de Vries, K. Brasel, B. Gliniak, L. T. Hollingsworth, K. S. Picha, H. J. McKenna, R. R. Splett, et al. 1993. Molecular cloning of a ligand for the Flt3/Flk-2 tyrosine kinase receptor: A proliferative factor for primitive hematopoietic cells. Cell 75:1157.
19. Lyman, S. D., L. James, S. Escobar, H. Downey, P. de Vries, K. Brasel, K. Stocking, M. P. Beckmann, N. G. Copeland, L. S. Cleveland, et al. 1995. Identification of soluble and membrane-bound isoforms of the murine Flt3-ligand generated by alternative splicing of mRNAs. Oncogene 10:149.
20. Brasel, K., S. Escobar, R. Anderberg, P. de Vries, H. J. Gruss, and S. D. Lyman. 1995. Expression of the Flt3 receptor and its ligand on hematopoietic cells. Leukemia 9:1212.
21. Rossner, M. T., G. A. McArthur, J. D. Allen, and D. Metcalf. 1994. Fms-like tyrosine kinase 3 catalytic domain can transduce a proliferative signal in FDC-P1 cells that is qualitatively similar to the signal delivered by c-Fms. Cell Growth Differ. 5:549.
22. Meierhoff, G., U. Dehmel, H. J. Gruss, O. Rosnet, D. Birnbaum, H. Quentmeier, W. Dirks, and H. G. Drexler. 1995. Expression of Flt3 receptor and Flt3-ligand in human leukemia-lymphoma cell lines. Leukemia 9:1368.
23. DaSilva, N., Z. B. Hu, W. Ma, O. Rosnet, D. Birnbaum, and H. G. Drexler. 1994. Expression of the Flt3 gene in human leukemia-lymphoma cell lines. Leukemia 8:885.
24. Maraskovsky, E., K. Brasel, M. Teepe, E. R. Roux, S. D. Lyman, K. Shortman, and H. J. McKenna. 1996. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J. Exp. Med. 184:1953.
25. Pulendran, B., J. Lingappa, M. K. Kennedy, J. Smith, M. Teepe, A. Rudensky, C. R. Maliszewski, and E. Maraskovsky. 1997. Developmental pathways of dendritic cells in vivo: distinct function, phenotype, and localization of dendritic cell subsets in Flt3 ligand treated mice. J. Immunol. 159:2222.
26. Pulendran, B., J. L. Smith, M. Jenkins, M. Schoenborn, E. Maraskovsky, and C. R. Maliszewski. 1998. Prevention of peripheral tolerance by a dendritic cell growth factor: Flt3 ligand as an adjuvant. J. Exp. Med. 188:2075.
27. Kremer, I. B., M. P. Gould, K. D. Cooper, and F. P. Heinzel. 2001. Pretreatment with recombinant Flt3 ligand partially protects against progressive cutaneous leishmaniasis in susceptible BALB/c mice. Infect. Immun. 69:673.
28. Steptoe, R. J., F. Fu, W. Li, M. L. Drakes, L. Lu, A. J. Demetris, S. Qian, H. J. McKenna, and A. W. Thomson. 1997. Augmentation of dendritic cells in murine organ donors by Flt3 ligand alters the balance between transplant tolerance and immunity. J. Immunol. 159:5483.
29. Qian, S., L. Lu, F. Fu, W. Li, F. Pan, R. J. Steptoe, F. G. Chambers, T. E. Starzl, J. J. Fung, and A. W. Thomson. 1998. Donor pretreatment with Flt-3 ligand augments antidonor cytotoxic T lymphocyte, natural killer, and lymphokine-activated killer cell activities within liver allografts and alters the pattern of intragraft apoptotic activity. Transplantation 65:1590.
30. Lynch, D. H., A. Andreasen, E. Maraskovsky, J. Whitmore, R. E. Miller, and J. C. Schuh. 1997. Flt3 ligand induces tumor regression and antitumor immune responses in vivo. Nat. Med. 3:625.
31. Chen, K., S. Braun, S. Lyman, Y. Fan, C. M. Traycoff, E. A. Wiebke, J. Gaddy, G. Sledge, H. E. Broxmeyer, and K. Cometta. 1997. Antitumor activity and immunotherapeutic properties of Flt3-ligand in a murine breast cancer model. Cancer Res. 57:3511.
32. Fernandez, N. C., A. Lozier, C. Flament, P. Ricciardi-Castagnoli, D. Bellet, M. Suter, M. Perricaudet, T. Tursz, E. Maraskovsky, and L. Zitvogel. 1999. Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat. Med. 5:405.
33. O'Keeffe, M., H. Hochrein, D. Vremec, J. Pooley, R. Evans, S. Woulfe, and K. Shortman. 2002. Effects of administration of progenipoietin 1, Flt-3 ligand, granulocyte colony-stimulating factor, and pegylated granulocyte-macrophage colony-stimulating factor on dendridc cell subsets in mice. Blood 99:2122.
34. DeMatteo, R. P., G. Chu, M. Ahn, E. Chang, C. F. Barker, and J. F. Markmann. 1997. Long-lasting adenovirus transgene expression in mice through neonatal intrathymic tolerance induction without the use of immunosuppression. J. Virol. 71:5330.
35. DeMatteo, R. P., G. Chu, M. Ahn, E. Chang, C. Burke, S. E. Raper, C. F. Barker, and J. F. Markmann. 1997. Immunologic barriers to hepatic adenoviral gene therapy for transplantation. Transplantation 63:315.
36. Rolink, A., F. Melchers, and J. Andersson. 1996. The SCID but not the RAG-2 gene product is required for Sμ-Sε heavy chain class switching. Immunity 5:319.
37. b-restricted, ovalbumin 257-264 determinant. Int. Immunol. 4:861.
38. Miller, G., S. Lahrs, V. G. Pillarisetty, A. B. Shah, and R. P. DeMatteo. 2002. Adenovirus infection enhances dendritic cell immunostimulatory properties and induces natural killer and T-cell-mediated tumor protection. Cancer Res. 62:5260.
39. Peron, J. M., C. Esche, V. M. Subbotin, C. Maliszewski, M. T. Lotze, and M. R. Shurin. 1998. Flt3-ligand administration inhibits liver metastases: role of NK cells. J. Immunol. 161:6164.
40. Pulendran, B., J. L. Smith, G. Caspary, K. Brasel, D. Pettit, E. Maraskovsky, and C. R. Maliszewski. 1999. Distinct dendritic cell subsets differentially regulate the class of immune response in vivo. Proc. Natl. Acad. Sci. USA 96:1036.
41. - subclasses of dendritic cells direct the development of distinct T helper cells in vivo. J. Exp. Med. 189:587.
42. Juan, T. S., I. K. McNiece, G. Van, D. Lacey, C. Hartley, P. McElroy, Y. Sun, J. Argento, D. Hill, X. Q. Yan, and F. A. Fletcher. 1997. Chronic expression of murine Flt3 ligand in mice results in increased circulating white blood cell levels and abnormal cellular infiltrates associated with splenic fibrosis. Blood 90:76.
43. + dendritic cells endowed with type I interferon production capacity and tolerogenic potential. Blood 100:383.
44. Vremec, D., and K. Shortman. 1997. Dendritic cell subtypes in mouse lymphoid organs: cross-correlation of surface markers, changes with incubation, and differences among thymus, spleen, and lymph nodes. J. Immunol. 159:565.
45. Shurin, M. R., P. P. Pandharipande, T. D. Zorina, C. Haluszezak, V. M. Subbotin, O. Hunter, A. Brumfield, W. J. Storkus, E. Maraskovsky, and M. T. Lotze. 1997. FLT3 ligand induces the generation of functionally active dendritic cells in mice. Cell. Immunol. 179:174.
46. high murine dendritic cells in vivo: a comparative analysis with Flt3 ligand. J. Immunol. 165:49.
47. Shurin, M. R., C. Esche, and M. T. Lotze. 1998. FLT3: receptor and ligand: biology and potential clinical application. Cytokine Growth Factor Rev. 9:37.
48. + suppressor T cells: more questions than answers. Nat. Rev. Immunol. 2:289.
49. + human thymocytes. J. Exp. Med. 196:379.
50. + immunoregulatory T cells: new therapeutics for graft- versus-host disease. J. Exp. Med. 196:401.
51. Merad, M., T. Sugie, E. G. Engleman, and L. Fong. 2002. In vivo manipulation of dendritic cells to induce therapeutic immunity. Blood 99:1676.